PubMed:28479494
Annnotations
{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/28479494","sourcedb":"PubMed","sourceid":"28479494","text":"Gastric mucosal devitalization reduces adiposity and improves lipid and glucose metabolism in obese rats.\nBACKGROUND AND AIMS: The gastric mucosa is an endocrine organ that regulates satiation pathways by expression of orexigenic and anorexigenic hormones. Vertical sleeve gastrectomy (VSG) excludes gastric mucosa and reduces gastric volume. Our study aimed to investigate the independent effects of altering gastric mucosa on obesity and its related comorbidities.\nMETHODS: Gastric mucosa devitalization (GMD) of 70% of the stomach was achieved by argon plasma coagulation in a high-fat diet rat model and was compared with VSG and sham surgery. In an 8-week follow-up study, we quantified body weight, visceral adiposity, insulin resistance index, cholesterol profiles, and free fatty acid profiles by enzyme-linked immunosorbent assay (ELISA). Following a 2-hour oral glucose tolerance test, the kinetics of ghrelin, glucagon-like peptide-1, peptide YY, and serum and liver bile acid levels were measured. Liver lipid content was quantified by ELISA.\nRESULTS: GMD resulted in significant reductions in body weight, visceral and subcutaneous adipose tissue, and hepatic steatosis as well as an improvement in lipid metabolism. GMD resulted in significant reductions in food intake and intestinal malabsorption of free fatty acids, both contributing to improved body composition and metabolic profile. Mechanistically, GMD resulted in a significant reduction in serum palmitate levels as well as an increase in serum and liver bile acid levels, known to alter glucose and lipid metabolism. Similar changes were noted when VSG rats were compared with sham surgery rats.\nCONCLUSIONS: Devitalization of gastric mucosa, independent of altering gastric volume, was able to reduce obesity-related comorbidities. The gastric mucosa may be a potential target for treating obesity and its associated comorbidities.","tracks":[{"project":"RDoCTask2SampleData","denotations":[{"id":"T1","span":{"begin":127,"end":256},"obj":"Sustained/Longer-Term Responsiveness to Reward Attainment"}],"attributes":[{"subj":"T1","pred":"source","obj":"RDoCTask2SampleData"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"RDoCTask2SampleData","color":"#93a2ec","default":true}]}]}}